Mme MEURISSE Aurélia

Fiche personne

Coordonnées

Unité de Méthodologie et de Qualité de Vie en Cancérologie (UMQVC)
CHRU Besançon
3 boulevard Fleming
25030 BESANCON

Territoire

Franche-Comté

Statut

ARC/TRC

Affiliation

Centre hospitalier régional universitaire de Besançon (CHRU Besançon)

Inserm UMR 1098 "Interaction Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique" (Inserm UMR1098 RIGHT)

Équipes/plateformes

Unité de méthodologie et de qualité de vie en cancérologie (UMQVC)

Recherche

Thématique de recherche :

Pôle data management

Publications

Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer.

Lecoester B, Xie Y, Sun X, Renaudin A, Ndao B, Boullerot L, Malfroy M, Arnier R, Boisson C, Laheurte C, Meurisse A, Chevalier C, Vulquin N, Thibouw D, Benhmida S, Pernot M, Vernerey D, Mirjolet C, Guo J, Boustani J, Adotevi O

Oncoimmunology. 2026 12 31;15(1):2635806

Germline Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France.

Meynard G, Pereira V, Paget-Bailly S, Klajer E, Mansi L, Chaigneau L, Meneveau N, Paillard MJ, Bazan F, Dobi E, Villanueva C, Selmani Z, Viot J, Dalens L, Goujon M, Collonge-Rame MA, Populaire C, Meurisse A, Pivot X, Curtit E

Cancers (Basel). 2026 03 6;18(5):

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.

Alves Costa Silva C, Machaalani M, Saliby RM, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, Vernerey D, Lee GM, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Choueiri TK, Albiges L

Nat Med. 2026 01 7;:

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.

Dutheil J, Pereira V, Boisson C, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Viot J, Meynard G, Goujon M, Dalens L, Dubourd C, Marchi S, Meneveau N, Vernerey D, Adotévi O, Meurisse A, Curtit E

Breast Cancer Res. 2025 12 24;27(1):220

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouché O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C,

Lancet Oncol. 2025 11 4;:

Impact of interprofessional education training on health students' perceptions of youth: findings from the Health Service by Health Students Program in France.

Pereira V, Pudlo M, Belpois S, Morgny C, Vuillemin X, Kubicki A, Girault M, Meurisse A, Bertrand X, Anxionnat R, Nerich V

Health Promot Int. 2025 10 30;40(6):

Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study.

Zaanan A, Bergen ES, Evesque L, Meurisse A, Artru P, Lecomte T, Bouché O, Lepère C, Ambrosini M, Coriat R, Lièvre A, Cohen R, Boige V, Louafi S, Bachet JB, Goyer S, Taieb J, Vernerey D, Blons H, Laurent-Puig P

J Natl Cancer Inst. 2025 08 20;:

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.

Laheurte C, Boullerot L, Ndao B, Malfroy M, Queiroz L, Guillaume P, Loyon R, Seffar E, Gravelin E, Renaudin A, Jacquin M, Meurisse A, Vernerey D, Ghiringhelli F, Godet Y, Genoley R, Jandus C, Borg C, Adotévi O

Cell Rep Med. 2025 06 17;:102196

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.

Depotte L, Nay P, Borg C, Meurisse A, Henriques J, Bennouna J, De La Fouchardière C, Tougeron D, Mazard T, Chibaudel B, Tournigand C, Vernerey D, Pigneur F, Andre T, Cohen R

J Immunother Cancer. 2025 05 19;13(5):

Health-state utility values and their time to deterioration in informal caregivers of older patients with chronic diseases.

Pozet A, Falcoz A, Roller C, Jai T, Meurisse A, Nerich V

Front Public Health. 2025 04 30;13:1531608

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).

Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, Hammel P, Regenet N, Taieb J, Turrini O, Paye F, Turpin A, Souche FR, Laurent C, Kianmanesh R, Michel P, Vernerey D, Mabrut JY, Turco C, Truant S, Sa Cunha A, ,

J Clin Oncol. 2025 04 4;:JCO2401378

Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.

Nerich V, Falcoz A, Nadin L, Meurisse A, Pechery A, Bourhis J, Sun XS, Thariat J

Radiother Oncol. 2025 01 19;204:110726

Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.

Damerval M, Bennani M, Rioufol C, Omrani S, Riboulet M, Etienne-Selloum N, Saint-Ghislain A, Leenhardt F, Schmitt A, Simon N, Clairet AL, Meurisse A, ,Nerich V

Support Care Cancer. 2024 04 30;32(5):318

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

French healthcare students and antibiotics: are they ready to promote their appropriate use?

Slekovec C, Lepiller Q, Anxionnat R, Mouillet S, Ferreira D, Guillaume A, Kubicki A, Le Bourvellec L, Maitre D, Meurisse A, August MJ, Bertrand X, Moulin T, Bouiller K, Nerich V

JAC Antimicrob Resist. 2024 02;6(1):dlad147

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion.

Gaiffe E, Vernerey D, Bardiaux L, Leroux F, Meurisse A, Bamoulid J, Courivaud C, Saas P, Hazzan M, Tiberghien P, Ducloux D

JAMA Netw Open. 2023 09 5;6(9):e2332821

Quality of Life and Needs in Caregivers: Results From the Prospective Multicentric Open-Label Randomized Study of Informal Caregivers of Elderly Patients.

Pozet A, Darnis S, Bonnet M, Meurisse A, Dabakuyo-Yonli TS, Lejeune C, Fagnoni P, Gaimard M, Manckoundia P, Quibel C, Marchand M, Anota A, Nerich V

Int J Public Health. 2023 08 30;68:1605459

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C

BMC Cancer. 2023 07 29;23(1):710

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.

Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, Vernerey D, Meurisse A, Borg C

Exp Hematol Oncol. 2023 07 21;12(1):63

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.

Bachet JB, Laurent-Puig P, Meurisse A, Bouché O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Taieb J

Eur J Cancer. 2023 06 7;189:112934

Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia.

Traore I, Eberst G, Claudé F, Laurent L, Meurisse A, Paget-Bailly S, Roux-Claudé P, Jacoulet P, Barnig C, Martarello R, Poirson B, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Pili-Floury S, Winiszewski H, Samain E, Capellier G, Westeel V

Nat Sci Sleep. 2022 12 22;14:2213-2225

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.

Debernardi A, Meurisse A, Prétet JL, Guenat D, Monnien F, Spehner L, Vienot A, Roncarati P, André T, Abramowitz L, Molimard C, Mougin C, Herfs M, Kim S, Borg C

Front Oncol. 2022 10 14;12:941676

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L

Front Oncol. 2022 07 19;12:957580

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study.

Gaiffe E, Vernerey D, Bardiaux L, Leroux F, Meurisse A, Bamoulid J, Courivaud C, Saas P, Tiberghien P, Ducloux D

Front Immunol. 2022 05 31;13:854850

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.

Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V

BMC Cancer. 2022 05 11;22(1):529

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia.

Eberst G, Claudé F, Laurent L, Meurisse A, Roux-Claudé P, Barnig C, Vernerey D, Paget-Bailly S, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Karaer S, Pili-Floury S, Winiszewski H, Samain E, Decavel P, Capellier G, Westeel V

Ann Intensive Care. 2022 Mar 9;12(1):23

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicenter study of 126 patients from the GRECCAR group.

Lakkis Z, Doussot A, Manfredelli S, Vernerey D, Meillat H, Ouaissi M, Cotte E, Faucheron JL, Piessen G, Tuech JJ, Lefevre JH, Panis Y, Beyer L, Brouquet A, Dumont F, Meurisse A, Rullier E, Heyd B,

Colorectal Dis. 2022 Jan 17;:

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S

Eur J Cancer. 2022 Jan 4;162:138-147

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.

Baumann A, Henriques J, Selmani Z, Meurisse A, Lepiller Q, Vernerey D, Valmary-Degano S, Paget-Bailly S, Riethmuller D, Ramanah R, Mougin C, Prétet JL

Cancers (Basel). 2021 Aug 18;13(16):

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T

J Immunother Cancer. 2020 Nov;8(2):

Anti-Telomerase CD4 Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV

Spehner L, Kim S, Vienot A, François E, Buecher B, Adotevi O, Vernerey D, Abdeljaoued S, Meurisse A, Borg C

Int J Mol Sci. 2020 Sep 17;21(18):

FOLFIRINOX de-escalation in advanced pancreatic cancer: a multicenter real-life study.

Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A

Oncologist. 2020 Sep 4;:

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.

Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Sourd SL, Evesque L, Meurisse A, Lièvre A, Vernerey D,

Int. J. Cancer. 2020 Jun 11;:

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group.

Doussot A, Vernerey D, Rullier E, H Lefevre J, Meillat H, Cotte E, Piessen G, Tuech JJ, Panis Y, Mege D, Meurisse A, De Bari B, Heyd B, Lakkis Z,

Ann. Surg. Oncol.. 2020 Jun 4;:

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.

Gassian N, Frontczak A, Mouillet G, Vernerey D, Manseur O, Goujon M, Meurisse A, Berthod D, Robert E, Calcagno F, Thiery-Vuillemin A

Bull Cancer. 2020 Jun;107(5S):eS16-eS21

FOLFOXIRI FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D

World J Gastrointest Oncol. 2020 Mar 15;12(3):332-346

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T,

Eur. J. Cancer. 2020 Mar 12;130:63-71

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.

Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C

Ther Adv Med Oncol. 2020 ;12:1758835920975356

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F

Clin Colorectal Cancer. 2019 Sep 4;:

Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P

Cancers (Basel). 2019 Jul 17;11(7):

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

Lakkis Z, Vernerey D, Mege D, Faucheron JL, Panis Y, Tuech JJ, Lefevre JH, Brouquet A, Dumont F, Borg C, Woronoff AS, Meurisse A, Heyd B, Rullier E,

Br J Surg. 2019 May 10;:

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A

Int J Oncol. 2019 04;54(4):1433-1445

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D, ,Evesque L, Heurgué A, Desramé J, Lecomte T, Cacheux W, Bachet JB, Phelip JM, Hautefeuille V, Hammoudi N, Mary F, Locher C, Bidault-Thirot A, Marthey L, Touchefeu Y, Moulin V, Zaanan A, Taïeb J, ,Casagrande M, Murgioni S, Santini D, Fornaro L, Montagnani F, Leone F, Faloppi L, Giommoni E, Lutrino SE, Palloni A, Brunetti O, Bergamo F, Vasile E, ,Malka D,

Eur. J. Cancer. 2019 Feb 28;111:94-106

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, Vernerey D, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A

Health Qual Life Outcomes. 2019 Feb 4;17(1):25

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).

Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C

Eur J Cancer. 2019 01;107:46-52

Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial.

Bernard-Tessier A, Jeannot E, David G, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bieche I, Pierga JY, Buecher B, Meurisse A, François E, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S

Clin. Cancer Res.. 2018 Nov 30;:

HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma.

Bernard-Tessier A, Jeannot E, Guenat D, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Francois E, Kim S, André T, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Meurisse A, Bidard FC, Borg C

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii29

Impact of BRCA status on outcomes and survival in high-risk early breast cancers.

Klajer E, Paget-Bailly S, Meynard G, Meurisse A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Montcuquet P, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Populaire C, Collonge-Rame MA, Gligorov J, Curtit E, Pivot X, Mansi L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii68

Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.

Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Murgioni S, Rousseau BJ, Scartozzi M, Dahan L, Boussaha T, Crusz S, Meurisse A, Lievre A, Vernerey D

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii261-viii262

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C

Lancet Oncol.. 2018 Jul 2;:

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of

Mouillet G, Paillard MJ, Maurina T, Vernerey D, Nguyen Tan Hon T, Almotlak H, Stein U, Calcagno F, Berthod D, Robert E, Meurisse A, Thiery-Vuillemin A

Trials. 2018 Apr 12;19(1):221

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P

Ann. Oncol.. 2018 Feb 9;:

Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.

Viot J, Bachour M, Meurisse A, Pivot X, Fiteni F

Breast. 2017 May;34:53-57

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C

Lancet Gastroenterol Hepatol. 2017 05;2(5):337-346

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D

J. Natl. Cancer Inst.. 2017 Apr;: